论文部分内容阅读
Objective:In order to evaluate potential application for diagnosis and prognosis of non-small celt lung cancer (NSCLC),as well as to determine its role in the pathogenesis of the disease,we prepared anti-human hnRNP A2/B1 polyclonal antibody.Methods:Prokaryotic expression vector of pET28a (+)-hnRNP A2/B1 was constructed and transformed into E.coli BL21.The recombinant protein induced by IPTG was purified and injected to rabbits for antibody preparation.Expression of hnRNP A2/B 1 was examined in 45 tissues of NSCLC and 16 inflammatory pseudotumor tissues of lung by immunohistochemistry with the antibody.The commercial hnRNPA2/B1 monoclonal antibody was used as a control.Results:(t) Polyclonal antibody against hnRNP A2/B1 with high title was obtained.(2) The positive staining in NSCLC tissues was 62.22%,which was substantially higher than that in normal tissues (40%,P＝0.035) or inflammatory pseudotumor tissues (31.25%,P＝0.033).(3) Expression of hnRNP A2/B1 positively correlated with age and the history of smoking,whereas it negatively correlated with differentiation staging of tumors.(4) Follow-up study showed that the survival time of patients with positive staining was significantly shorter than that of patients without hnRNP A2/B1 expression (P＝0.048).Conclusion:It is successful to make the recombinant protein and prepare the polyclonal antibody agonist human hnRNP A2/B1.It may be a valuable marker for the diagnosis and prognosis of NSCLC.Our results provide a basis for further study in clinical application.